Eribulin Mesilate injection

DRUG2 trials

Sponsors

Shanghai Yizhong Pharmaceutical Co., Ltd., MedSIR

Conditions

Breast CancerHER 2 Positive Advanced Breast CancerMetastatic Breast Cancer (MBC)

Phase 1

Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer

Not yet recruitingNCT07494448

MedSIRBreast Cancer, HER 2 Positive Advanced Breast Cancer

Start: 2026-07-01End: 2028-05-31Target: 24Updated: 2026-03-27

Phase 3

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

RecruitingNCT06143553

Shanghai Yizhong Pharmaceutical Co., Ltd.Metastatic Breast Cancer (MBC)

Start: 2023-09-25End: 2025-12-31Target: 168Updated: 2024-11-29